These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34889388)

  • 1. TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
    Hochhaus A; Ernst T
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):106-112. PubMed ID: 34889388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
    Kumagai T
    Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
    Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
    Expert Opin Drug Saf; 2024 Aug; 23(8):969-979. PubMed ID: 38873693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
    Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
    Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 8. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
    Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
    Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
    Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
    Saglio G; Gale RP
    Br J Haematol; 2020 Aug; 190(3):318-327. PubMed ID: 32057102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
    Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.
    Cerveira N; Bizarro S; Teixeira MR; Mariz JM
    Curr Treat Options Oncol; 2021 Apr; 22(6):49. PubMed ID: 33866455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
    Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S
    Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?
    Stagno F; Breccia M; Di Raimondo F
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1075-1081. PubMed ID: 32985290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
    Yamaguchi H; Takezako N; Ohashi K; Oba K; Kumagai T; Kozai Y; Wakita H; Yamamoto K; Fujita A; Igarashi T; Yoshida C; Ohyashiki K; Okamoto S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Hematol; 2020 Mar; 111(3):401-408. PubMed ID: 31894533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic myeloid leukemia: state-of-the-art management].
    Takahashi N
    Rinsho Ketsueki; 2018; 59(6):747-754. PubMed ID: 29973455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
    Machova Polakova K; Zizkova H; Zuna J; Motlova E; Hovorkova L; Gottschalk A; Glauche I; Koblihova J; Pecherkova P; Klamova H; Stastna Markova M; Srbova D; Benesova A; Polivkova V; Jurcek T; Zackova D; Mayer J; Ernst T; Mahon FX; Saussele S; Roeder I; Cross NCP; Hochhaus A
    Leukemia; 2020 Aug; 34(8):2113-2124. PubMed ID: 32472084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
    Breccia M; Foà R
    Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.